Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 10, 2006, Pages 2672-2676

  Hennequin, Laurent F A ^a   Ballard, Peter ^a   Boyle, F Tom ^a   Delouvrié, Bénédicte ^a   Ellston, Rebecca P A ^a   Halsall, Chris T ^a   Harris, Craig S ^a   Hudson, Kevin ^a   Kendrew, Jane ^a   Pease, J Elizabeth ^a   Ross, Helen S ^a   Smith, Peter ^a   Vincent, Jennifer L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anilinoquinazoline; EGFR tyrosine kinase; Kinase inhibition

Indexed keywords

ALANINE DERIVATIVE; AMIDE; ANILINE DERIVATIVE; AZETIDINE DERIVATIVE; CARBON; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; HEXAMETHONIUM BROMIDE; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG POTENCY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; DOGS; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; CANIS FAMILIARIS;

EID: 33646536091     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.02.025     Document Type: Article

References (16)

1. Woodburn J.R. Pharmacol. Ther. 82 (1999) 241
2. Muhsin M., Graham J., and Kirkpatrick P. Nat. Rev. Drug Disc. 2 (2003) 515
3. Herbst R.S., Fukuoka M., and Baselga J. Nat. Rev. Cancer 4 (2004) 956
4. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., and Richards L. Bioorg. Med. Chem. Lett. 11 (2001) 1911
5. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. Cancer Res. 62 (2002) 5749
6. Dowell J., Minna J.D., and Kirkpatrick P. Nat. Rev. Drug Disc. 4 (2005) 13
7. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., and Shewchuk L. Cancer Res. 64 (2004) 6652
8. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Plé P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., and Curwen J.O. J. Med. Chem. 45 (2002) 1300
9. Graham J., Muhsin M., and Kirkpatrick P. Nat. Rev. Drug Disc. 3 (2004) 549
10. Traxler P. Exp. Opin. Ther. Patents 7 (1997) 571
11. Traxler P. Exp. Opin. Ther. Patents 8 (1998) 1599
12. Stamos J., Sliwkowski M.X., and Eigenbrot C. J. Biol. Chem. 277 (2002) 46265
13. For a full description of synthesis and biological assays, see: (a) Hennequin, L. F. A.; Halsall, C. T. WO2005/026156; 2005.
14. Delouvrié, B.; Harris, C. S.; Hennequin, L. F. A.; Halsall, C. T.; Pease, J. E.; Smith, P. M. WO2005/075439; 2005.
15. Ballard, P.; Bradbury, R. H.; Harris, C. S.; Hennequin, L. F. H.; Hickinson, M.; Johnson, P. D.; Kettle, J. G.; Klinoswka, T.; Leach, A. G.; Morgentin, R.; Pass, M.; Ogilvie, D. J.; Olivier, A.; Warin, N.; Williams, E. J. Bioorg. Med. Chem. Lett., in press.
16. Examples of kinases tested in our selectivity panels: MAP kinase, JNK, PKA, PDK1, SGK, CDKs, Src, KDR, GSK3b, AMPK, CHK1, SAP kinase, ROCK-ll and LCK.